爪真菌症の世界市場レポート 2025年

爪真菌症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.9％で48億1,000万米ドルに成長します。予測期間の成長は、併用薬物療法の採用、ヘルスケア支出の増加、爪真菌症に関する啓発キャンペーンの拡大、遠隔医療サービスの拡大、外用薬製剤の進歩などに起因すると考えられます。予測期間における主な動向としては、爪真菌症の診断と管理におけるデジタル技術の統合、市販（OTC）抗真菌製品の増加、患者にやさしい治療レジメンの開発、爪真菌症治療における個別化医療の重視、研究開発における製薬企業間の連携などが挙げられます。

糖尿病の有病率の増加は、爪真菌症市場の今後の成長を牽引すると予想されます。糖尿病は、膵臓によるインスリン分泌不全、またはインスリンを効果的に使用できない体質のいずれかを特徴とする慢性疾患です。糖尿病患者は、一般的な足の問題である爪真菌症に特にかかりやすく、この感染症に関連する合併症の管理は健康にとって極めて重要です。その結果、糖尿病の罹患率の増加が爪真菌症市場の需要を押し上げています。例えば、2024年6月、英国の政府機関である国民保健サービス（NHS）は、2023年にイングランドで50万人以上（549,000人）が2型糖尿病を発症するリスクがあると確認されたと報告しました。これにより、一般開業医に登録された非糖尿病性高血糖、または糖尿病予備軍の総数は3,615,330人に増加し、2022年の3,065,825人から20％近い大幅な増加を反映しました。このため、糖尿病罹患率の増加が爪真菌症市場の拡大に拍車をかけています。

製薬企業の世界化は、爪真菌症市場の拡大に貢献するものと思われます。この動向は、製薬企業が国内市場や地域市場を超えて世界規模で事業を展開することを意味します。世界製薬企業は、爪真菌症を含む様々な健康状態に関する啓発キャンペーンや教育イニシアチブを実施する上で重要な役割を果たしています。このようなイニシアチブは、医療専門家や一般市民の間で、疾患の有病率や利用可能な治療法に関する認識を高めることに貢献しています。一例として、ドイツを拠点とする対外貿易事務所であるドイツ貿易投資庁のデータによると、世界第4位、欧州最大の医薬品市場であるドイツでは、医薬品売上高が5.4％増加し、2022年には565億ユーロに達することが明らかになっています。特に生物製剤の伸びが顕著で、2021年から2022年にかけて10.5%に達し、2022年には178億ユーロの売上高を計上し、同国の医薬品事業全体の3分の1を占める。このように、製薬企業の世界化は、爪真菌症市場の成長を促進する上で重要な役割を果たしています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界爪真菌症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の爪真菌症市場：成長率分析
• 世界の爪真菌症市場の実績：規模と成長, 2019-2024
• 世界の爪真菌症市場の予測：規模と成長, 2024-2029, 2034F
• 世界爪真菌症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の爪真菌症市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遠位爪下爪真菌症（DSO）
• ホワイトサーフィシャル爪真菌症（WSO）
• 近位爪下爪真菌症（PSO）
• カンジダ爪真菌症
• 世界の爪真菌症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物治療
• 局所療法
• その他の治療法
• 世界の爪真菌症市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の爪真菌症市場、遠位爪下節のサブセグメンテーション爪真菌症（DSO）、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮膚糸状菌感染症
• 混合感染
• 世界の爪真菌症市場、ホワイトサーフィシャル爪真菌症（WSO）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トリコフィトン・メンタグロフィテス感染症
• その他の非皮膚糸状菌感染症
• 世界の爪真菌症市場、近位爪下骨のサブセグメンテーション爪真菌症（PSO）、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 爪乾癬に関連する
• 免疫不全患者における真菌感染症
• 世界の爪真菌症市場、カンジダ爪真菌症の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• カンジダ爪感染症
• 真菌・カンジダ混合感染症
• 世界の爪真菌症市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全爪異栄養症
• セカンダリ爪真菌症

第7章 地域別・国別分析

• 世界の爪真菌症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の爪真菌症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 爪真菌症市場：競合情勢
• 爪真菌症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sandoz International GmbH
• Bausch Health Companies Inc.
• Perrigo Company plc
• Galderma Laboratories LP
• Aurobindo Pharma Limited
• Cipla Inc.
• Dr.Reddy's Laboratories Ltd.
• Apotex Inc
• Lupin Limited
• Amneal Pharmaceuticals Inc.
• Alembic Pharmaceuticals Inc.
• Kaken Pharmaceutical Co. Ltd.
• Mayne Pharma Group Limited
• Wockhardt Ltd.
• Jubilant Cadista Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 爪真菌症市場2029：新たな機会を提供する国
• 爪真菌症市場2029：新たな機会を提供するセグメント
• 爪真菌症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Onychomycosis is a fungal infection that affects the nail matrix, bed, or plate, impacting both toenails and fingernails. This condition can result in discoloration, thickening, and crumbling of the nails. The primary goal of treatment is to eliminate the infection, restore the health and appearance of the nails, and prevent the fungus from spreading to other nails or the surrounding skin.

The primary types of onychomycoses include distal subungual onychomycosis (DSO), white superficial onychomycosis (WSO), proximal subungual onychomycosis (PSO), candida onychomycosis, and others. Distal subungual onychomycosis (DSO) specifically targets the nails of the feet, and treatment options vary, encompassing oral antifungal drugs, topical antifungal treatments, or a combination of both. The therapeutic approaches involve drug treatment, topical therapy, and other interventions, with distribution channels including hospital pharmacies, retail pharmacies, and other relevant outlets.

The onychomycosis research report is one of a series of new reports from The Business Research Company that provides onychomycosis market statistics, including the onychomycosis industry's global market size, regional shares, competitors with onychomycosis market share, detailed onychomycosis market segments, market trends and opportunities, and any further data you may need to thrive in the onychomycosis industry. This onychomycosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The onychomycosis market size has grown strongly in recent years. It will grow from $3.63 billion in 2024 to $3.83 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to limited treatment options, an aging population, increased incidence of diabetes, expansion of the pharmaceutical industry, and growing awareness of fungal infections

The onychomycosis market size is expected to see strong growth in the next few years. It will grow to $4.81 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to the adoption of combination drug therapies, increasing healthcare expenditure, growing awareness campaigns for onychomycosis, expansion of telemedicine services, and advances in topical drug formulations. Major trends in the forecast period include the integration of digital technologies in onychomycosis diagnosis and management, rise in over-the-counter (OTC) antifungal products, development of patient-friendly treatment regimens, emphasis on personalized medicine in onychomycosis treatment, collaboration between pharmaceutical companies for research and development.

The increasing prevalence of diabetes is anticipated to drive the growth of the onychomycosis market in the future. Diabetes is a chronic condition characterized by either inadequate insulin production by the pancreas or the body's inability to effectively use insulin. Individuals with diabetes are particularly susceptible to onychomycosis, a common foot issue, and managing complications associated with this infection is crucial for their health. Consequently, the rising incidence of diabetes is boosting demand in the onychomycosis market. For example, in June 2024, the National Health Service (NHS), a UK government agency, reported that in 2023, over half a million (549,000) more individuals in England were identified as at risk of developing type 2 diabetes. This increased the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a general practitioner to 3,615,330, reflecting a significant rise from 3,065,825 in 2022, or nearly 20%. Therefore, the growing incidence of diabetes is fueling the expansion of the onychomycosis market.

The globalization of pharmaceutical companies is poised to contribute to the expansion of the onychomycosis market. This trend involves pharmaceutical companies extending their operations beyond domestic or local markets to operate on a global scale. Global pharmaceutical companies play a vital role in conducting awareness campaigns and educational initiatives on various health conditions, including onychomycosis. Such initiatives contribute to increased awareness among healthcare professionals and the general public regarding the condition's prevalence and available treatment options. As an example, data from Germany Trade and Invest, a Germany-based office for foreign trade, reveals that Germany, being the fourth-largest pharmaceutical market globally and the largest in Europe, experienced a 5.4% increase in pharmaceutical sales to reach EUR 56.5 billion in 2022. The growth in biologics was particularly notable, reaching 10.5% between 2021 and 2022, generating EUR 17.8 billion in revenue in 2022 and constituting one-third of the country's entire pharmaceutical business. The globalization of pharmaceutical companies is thus playing a significant role in driving the growth of the onychomycosis market.

Product innovation is a significant trend gaining traction in the onychomycosis market. Leading companies in this sector are developing novel products to maintain their competitive edge. For example, in January 2024, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical firm, announced that the Food and Drug Administration (FDA) approved VTR-297 for the treatment of onychomycosis. VTR-297 is a small molecule histone deacetylase (HDAC) inhibitor that demonstrates antifungal activity specifically against dermatophytes and other fungi. This mechanism is essential for effectively targeting the pathogens responsible for onychomycosis. The drug is intended for topical application, enabling direct application to the affected nails. This localized delivery system reduces systemic exposure and minimizes potential side effects linked to oral antifungal treatments.

Key players in the onychomycosis market are also developing innovative formulations to strengthen their market position. These formulations enhance treatment outcomes and address specific challenges related to the condition. For instance, in February 2024, Moberg Pharma AB, a Sweden-based pharmaceutical company, launched MOB-015, a proprietary topical formulation of terbinafine aimed at delivering effective concentrations directly to the nail and nail bed while reducing the risk of systemic exposure linked to oral terbinafine. The product has received recommendations for national approval in 13 European countries and is marketed in Sweden under the brand name Terclara. The approval is supported by two Phase 3 trials demonstrating that MOB-015 achieved superior mycological cure rates (76% compared to up to 42% for comparators) and a significantly higher complete cure rate, with no serious adverse reactions reported.

In July 2023, Cipher Pharmaceuticals Inc., a Canadian pharmaceutical company, formed a partnership with Moberg Pharma to commercialize MOB-015, a topical nail fungus treatment known for its superior clinical cure rates. Moberg Pharma secured EU approval and intends to launch the product across 13 European countries. Moberg Pharma AB is a Sweden-based pharmaceutical firm that specializes in treatments for onychomycosis.

Major companies operating in the onychomycosis market include Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Galderma Laboratories LP, Aurobindo Pharma Limited, Cipla Inc., Dr.Reddy's Laboratories Ltd., Apotex Inc, Lupin Limited, Amneal Pharmaceuticals Inc., Alembic Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Mayne Pharma Group Limited, Wockhardt Ltd., Jubilant Cadista Pharmaceuticals Inc., Moberg Pharma AB, Medimetriks Pharmaceuticals Inc., Blueberry Therapeutics Ltd., Hallux Inc., NovaBiotics Ltd., Zydus Cadila Healthcare Limited.

North America was the largest region in the onychomycosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the onychomycosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The onychomycosis market includes revenues earned by services such as combination therapy, oral antifungal medications, itraconazole, ketoconazole, griseofulvin, and terbinafine. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Onychomycosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on onychomycosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for onychomycosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The onychomycosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Distal Subungual Onychomycosis (DSO); White Superficial Onychomycosis (WSO); Proximal Subungual Onychomycosis (PSO); Candida Onychomycosis; Other Types
• 2) By Treatment: Drug Treatment; Topical Therapy; Other Treatments
• 3) By Distribution Channel: Hospitals Pharmacies; Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Distal Subungual Onychomycosis (DSO): Dermatophyte Infections; Mixed Infections
• 2) By White Superficial Onychomycosis (WSO): Trichophyton Mentagrophytes Infections; Other Non-Dermatophyte Infections
• 3) By Proximal Subungual Onychomycosis (PSO): Associated with Nail Psoriasis; Fungal Infections In Immunocompromised Patients
• 4) By Candida Onychomycosis: Candidal Nail Infections; Mixed Fungal-Candida Infections
• 5) By Other Types: Total Nail Dystrophy; Secondary Onychomycosis
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Merck & Co. Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Onychomycosis Market Characteristics

3. Onychomycosis Market Trends And Strategies

4. Onychomycosis Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Onychomycosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Onychomycosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Onychomycosis Market Growth Rate Analysis
• 5.4. Global Onychomycosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Onychomycosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Onychomycosis Total Addressable Market (TAM)

6. Onychomycosis Market Segmentation

• 6.1. Global Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Distal Subungual Onychomycosis (DSO)
• White Superficial Onychomycosis (WSO)
• Proximal Subungual Onychomycosis (PSO)
• Candida Onychomycosis
• 6.2. Global Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Treatment
• Topical Therapy
• Other Treatments
• 6.3. Global Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.4. Global Onychomycosis Market, Sub-Segmentation Of Distal Subungual Onychomycosis (DSO), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dermatophyte Infections
• Mixed Infections
• 6.5. Global Onychomycosis Market, Sub-Segmentation Of White Superficial Onychomycosis (WSO), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trichophyton Mentagrophytes Infections
• Other Non-Dermatophyte Infections
• 6.6. Global Onychomycosis Market, Sub-Segmentation Of Proximal Subungual Onychomycosis (PSO), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Associated with Nail Psoriasis
• Fungal Infections In Immunocompromised Patients
• 6.7. Global Onychomycosis Market, Sub-Segmentation Of Candida Onychomycosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Candidal Nail Infections
• Mixed Fungal-Candida Infections
• 6.8. Global Onychomycosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Total Nail Dystrophy
• Secondary Onychomycosis

7. Onychomycosis Market Regional And Country Analysis

• 7.1. Global Onychomycosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Onychomycosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Onychomycosis Market

• 8.1. Asia-Pacific Onychomycosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Onychomycosis Market

• 9.1. China Onychomycosis Market Overview
• 9.2. China Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Onychomycosis Market

• 10.1. India Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Onychomycosis Market

• 11.1. Japan Onychomycosis Market Overview
• 11.2. Japan Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Onychomycosis Market

• 12.1. Australia Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Onychomycosis Market

• 13.1. Indonesia Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Onychomycosis Market

• 14.1. South Korea Onychomycosis Market Overview
• 14.2. South Korea Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Onychomycosis Market

• 15.1. Western Europe Onychomycosis Market Overview
• 15.2. Western Europe Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Onychomycosis Market

• 16.1. UK Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Onychomycosis Market

• 17.1. Germany Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Onychomycosis Market

• 18.1. France Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Onychomycosis Market

• 19.1. Italy Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Onychomycosis Market

• 20.1. Spain Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Onychomycosis Market

• 21.1. Eastern Europe Onychomycosis Market Overview
• 21.2. Eastern Europe Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Onychomycosis Market

• 22.1. Russia Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Onychomycosis Market

• 23.1. North America Onychomycosis Market Overview
• 23.2. North America Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Onychomycosis Market

• 24.1. USA Onychomycosis Market Overview
• 24.2. USA Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Onychomycosis Market

• 25.1. Canada Onychomycosis Market Overview
• 25.2. Canada Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Onychomycosis Market

• 26.1. South America Onychomycosis Market Overview
• 26.2. South America Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Onychomycosis Market

• 27.1. Brazil Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Onychomycosis Market

• 28.1. Middle East Onychomycosis Market Overview
• 28.2. Middle East Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Onychomycosis Market

• 29.1. Africa Onychomycosis Market Overview
• 29.2. Africa Onychomycosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Onychomycosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Onychomycosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Onychomycosis Market Competitive Landscape And Company Profiles

• 30.1. Onychomycosis Market Competitive Landscape
• 30.2. Onychomycosis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Onychomycosis Market Other Major And Innovative Companies

• 31.1. Sandoz International GmbH
• 31.2. Bausch Health Companies Inc.
• 31.3. Perrigo Company plc
• 31.4. Galderma Laboratories LP
• 31.5. Aurobindo Pharma Limited
• 31.6. Cipla Inc.
• 31.7. Dr.Reddy's Laboratories Ltd.
• 31.8. Apotex Inc
• 31.9. Lupin Limited
• 31.10. Amneal Pharmaceuticals Inc.
• 31.11. Alembic Pharmaceuticals Inc.
• 31.12. Kaken Pharmaceutical Co. Ltd.
• 31.13. Mayne Pharma Group Limited
• 31.14. Wockhardt Ltd.
• 31.15. Jubilant Cadista Pharmaceuticals Inc.

32. Global Onychomycosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Onychomycosis Market

34. Recent Developments In The Onychomycosis Market

35. Onychomycosis Market High Potential Countries, Segments and Strategies

• 35.1 Onychomycosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Onychomycosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Onychomycosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer